Ginkgo biloba extract possess several promising biological activities; currently, it is clinically employed in the management of several diseases. This research work aimed to extrapolate the
antioxidant and anti-inflammatory effects of Ginkgo biloba (Gb) in
methotrexate (MTX)-induced liver toxicity model. These effects were analyzed using different in vivo experimental approaches and by bioinformatics analysis. Male SD rats were grouped as follows: saline; MTX; Gb (pretreated for seven days with 60, 120, and 180 mg/kg daily dose before MTX treatment);
silymarin (followed by MTX treatment); Gb 180 mg/kg daily only; and
silymarin only. Histopathological results revealed that MTX induced marked hepatic injury, associated with a substantial surge in various hepatic
enzymes such as
alanine transaminase (ALT),
aspartate transaminase (AST), and serum
alkaline phosphatase (ALP). Furthermore, MTX caused the triggering of oxidative distress associated with a depressed
antioxidant system. All these injury markers contributed to a significant release of apoptotic (
caspase-3 and c-Jun N-terminal
kinases (JNK)) and
tumor necrosis factor (TNF-α)-like inflammatory mediators. Treatment with Gb counteracts MTX-mediated apoptosis and
inflammation dose-dependently along with modulating the innate antioxidative mechanisms such as
glutathione (GSH) and
glutathione S-transferase (GST). These results were further supplemented by in silico study to analyze
drug-receptor interactions (for several Gb constituents and target
proteins) stabilized by a low energy value and with a good number of hydrogen bonds. These findings demonstrated that Gb could ameliorate MTX-induced elevated liver
reactive oxygen species (ROS) and
inflammation, possibly by JNK and TNF-α modulation.